[go: up one dir, main page]

NO933114L - Fremstilling av faktor ix - Google Patents

Fremstilling av faktor ix

Info

Publication number
NO933114L
NO933114L NO93933114A NO933114A NO933114L NO 933114 L NO933114 L NO 933114L NO 93933114 A NO93933114 A NO 93933114A NO 933114 A NO933114 A NO 933114A NO 933114 L NO933114 L NO 933114L
Authority
NO
Norway
Prior art keywords
factor
contained
preparations
disclosed
derived
Prior art date
Application number
NO93933114A
Other languages
English (en)
Other versions
NO315856B1 (no
NO933114D0 (no
Inventor
Chin C Huang
Takashi Enkoji
Laura Ho
Richard R Kleszynski
Richard L Weeks
Fred Feldman
Original Assignee
Rhone Poulenc Rorer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Int filed Critical Rhone Poulenc Rorer Int
Publication of NO933114D0 publication Critical patent/NO933114D0/no
Publication of NO933114L publication Critical patent/NO933114L/no
Publication of NO315856B1 publication Critical patent/NO315856B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)
NO19933114A 1991-03-01 1993-09-01 Vandig lösning av delvis renset faktor IX, samt fremgangsmåte for å rense faktor IX fra andre proteiner og makromolekyler i en lösning medslike NO315856B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66292791A 1991-03-01 1991-03-01
PCT/US1992/001600 WO1992015324A1 (en) 1991-03-01 1992-02-26 Preparation of factor ix

Publications (3)

Publication Number Publication Date
NO933114D0 NO933114D0 (no) 1993-09-01
NO933114L true NO933114L (no) 1993-09-01
NO315856B1 NO315856B1 (no) 2003-11-03

Family

ID=24659784

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19933114A NO315856B1 (no) 1991-03-01 1993-09-01 Vandig lösning av delvis renset faktor IX, samt fremgangsmåte for å rense faktor IX fra andre proteiner og makromolekyler i en lösning medslike

Country Status (17)

Country Link
US (3) US6063909A (no)
EP (1) EP0573605B1 (no)
JP (1) JP3418621B2 (no)
AT (1) ATE195877T1 (no)
AU (1) AU671586B2 (no)
BR (1) BR9205700A (no)
CA (1) CA2105282C (no)
DE (1) DE69231401T2 (no)
DK (1) DK0573605T3 (no)
ES (1) ES2150914T3 (no)
FI (1) FI114969B (no)
GR (1) GR3034946T3 (no)
MX (1) MX9200882A (no)
NO (1) NO315856B1 (no)
RU (1) RU2142806C1 (no)
SG (1) SG48282A1 (no)
WO (1) WO1992015324A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU671586B2 (en) * 1991-03-01 1996-09-05 Aventis Behring Llc Preparation of factor IX
EP0658168B1 (en) * 1992-08-27 2000-11-15 Stichting Sanquin Bloedvoorziening Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein
DE19506633A1 (de) 1995-02-25 1996-08-29 Octapharma Ag Verfahren zur Herstellung von Faktor IX aus biologischen Quellen
EP0937158B1 (de) * 1996-10-31 2000-12-27 Boehringer Mannheim Gmbh VERFAHREN ZUR BESTIMMUNG DER KATALYTISCHEN AKTIVITÄT VON FAKTOR IXa
RU2163140C1 (ru) * 2000-07-05 2001-02-20 Гематологический научный центр РАМН Концентрат фактора ix системы свертывания крови и способ его получения
AU2002226028A1 (en) * 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
KR20060034216A (ko) * 2003-04-09 2006-04-21 넥타르 테라퓨틱스 응고 인자의 흡입에 의한 혈우병 치료
WO2006017263A1 (en) 2004-07-12 2006-02-16 Taro Pharmaceutical Industries Ltd. Topical gel formulation comprising organophosphate insecticide and its preparation thereof
US8158139B2 (en) * 2004-07-12 2012-04-17 Taro Pharmaceuticals North America, Inc. Topical gel formulation comprising organophosphate insecticide and preparation thereof
US7560445B2 (en) 2005-07-06 2009-07-14 Taro Pharmaceuticals North America, Inc. Process for preparing malathion for pharmaceutical use
US9896677B2 (en) 2010-01-18 2018-02-20 Novo Nordisk Health Care Ag Purification of blood coagulation factors
EP3133157B1 (en) * 2010-03-30 2019-05-08 Octapharma AG A process for purifying vitamin k dependent proteins
WO2012082933A1 (en) 2010-12-15 2012-06-21 Baxter International, Inc. Eluate collection using conductivity gradient
US9663553B2 (en) 2014-01-29 2017-05-30 Hemarus Therapeutics Limited Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU552085A1 (ru) * 1967-06-21 1977-03-30 Средство дл лечени нарушений свертывающей системы крови при тромбоцитопенических состо ни х различного происхождени и дл стимул ции гемоопоэза "эритрофосфатид"
AT368883B (de) * 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
DE3045153A1 (de) * 1980-11-29 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
DE3101752A1 (de) * 1981-01-21 1982-08-26 Behringwerke Ag, 3550 Marburg "verfahren zur reinigung der blutgerinnungsfaktoren ii, vii, ix und/oder x und danach hergestellte praeparationen"
US4447416A (en) * 1982-04-28 1984-05-08 American National Red Cross Plasma protein concentrates of reduced thrombogenicity and their use in clinical replacement therapy
US4379085A (en) * 1982-05-14 1983-04-05 American National Red Cross Heat stabilization of plasma proteins
EP0118256B1 (en) * 1983-03-04 1992-05-13 Scripps Clinic And Research Foundation Immunoadsorbent, and method of recovering vitamin-k dependent protein therewith
US5055557A (en) * 1983-03-04 1991-10-08 Scripps Clinic & Research Foundation Ultrapurification of factor IX and other vitamin K-dependent proteins
US5614500A (en) 1983-03-04 1997-03-25 The Scripps Research Institute Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography
EP0124506B1 (de) * 1983-05-02 1988-08-17 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Verfahren zur Inaktivierung von vermehrungsfähigen Krankheitserregern
JPS60132912A (ja) * 1983-12-21 1985-07-16 Kao Corp シヤンプ−組成物
EP0218713B1 (en) * 1985-04-22 1992-03-25 Genetics Institute, Inc. High yield production of active factor ix
US4786726A (en) * 1986-01-06 1988-11-22 Blood Systems, Inc. Factor IX therapeutic blood product, means and methods of preparing same
FR2600334B1 (fr) 1986-06-23 1989-05-12 Transgene Sa Vecteurs d'integration dans les cellules eucaryotes assurant l'expression du facteur ix, lignees celullaires obtenues et procede pour leur preparation
US4725673A (en) * 1986-08-29 1988-02-16 Alpha Therapeutic Corporation Plasma fraction purification using silica resin bound to a ligand
EP0317376B2 (fr) 1987-10-23 1996-04-03 Centre Regional De Transfusion Sanguine De Lille Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques
JPH01258700A (ja) 1988-04-05 1989-10-16 Green Cross Corp:The 血液凝固第４因子の精製方法
DE3826792C1 (no) * 1988-08-06 1989-07-06 Biotest Pharma Gmbh, 6072 Dreieich, De
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
DE3914869C1 (no) * 1989-05-05 1990-08-09 Biotest Pharma Gmbh, 6072 Dreieich, De
AT402261B (de) 1991-01-25 1997-03-25 Immuno Ag Komplex enthaltend den gerinnungsfaktor ix
AU671586B2 (en) * 1991-03-01 1996-09-05 Aventis Behring Llc Preparation of factor IX

Also Published As

Publication number Publication date
CA2105282C (en) 2002-09-24
AU671586B2 (en) 1996-09-05
JP3418621B2 (ja) 2003-06-23
SG48282A1 (en) 1998-04-17
MX9200882A (es) 1992-09-01
NO315856B1 (no) 2003-11-03
US6043215A (en) 2000-03-28
DE69231401T2 (de) 2001-02-08
WO1992015324A1 (en) 1992-09-17
FI933814A0 (fi) 1993-09-01
EP0573605A4 (en) 1994-11-23
GR3034946T3 (en) 2001-02-28
RU2142806C1 (ru) 1999-12-20
NO933114D0 (no) 1993-09-01
FI114969B (fi) 2005-02-15
DK0573605T3 (da) 2001-01-02
US6063909A (en) 2000-05-16
ATE195877T1 (de) 2000-09-15
AU1642992A (en) 1992-10-06
EP0573605A1 (en) 1993-12-15
ES2150914T3 (es) 2000-12-16
DE69231401D1 (de) 2000-10-05
EP0573605B1 (en) 2000-08-30
JPH06505494A (ja) 1994-06-23
BR9205700A (pt) 1994-06-28
US6280729B1 (en) 2001-08-28
CA2105282A1 (en) 1992-09-02
FI933814L (fi) 1993-09-01

Similar Documents

Publication Publication Date Title
NO933114D0 (no) Fremstilling av faktor ix
DE59008910D1 (de) Stabile injizierbare lösungen von faktor viii.
ATE148165T1 (de) Stabilisierung von hochgereinigten proteinen
RU93053992A (ru) Способ очистки и хранения фактора ix, водный раствор очищенного фактора ix, композиция, содержащая фактор ix, способ лечения
ZA200005696B (en) Stable concentrated rare earth carboxylate liquids.
SE8701921L (sv) Ny farmaceutisk anvendning
DE69016087D1 (de) Stabile Lösungen von Rebeccamycinderivaten sowie deren Herstellung.
NO923333L (no) Vasoaktive vasotocinderivater
LU90993I2 (fr) Xigris-drotrécogine alfa(activée) et ses dérivés pharmaceutiquement acceptables
ES2052529T3 (es) Procedimiento para la preparacion de compuestos cromogenos.
SE8704832L (en) Prepn. for dissolving caries - comprises nitrogen-contg. cpds. and sodium hypochlorite
ATE147268T1 (de) Hypoglycemische peptide
ATE94168T1 (de) Peptide.
ATE81464T1 (de) Verfahren zur herstellung wundheilungsfoerdernder praeparationen und solche praeparationen.
DE68905796D1 (de) Chromoglycinsaeure-natriumsalz enthaltende aerosolzubereitungen.
ATE193537T1 (de) Phosphorylierte derivate von verbindungen mit antiinflammatorischen oder analgetischer wirkung
JPS5732225A (en) Human plasmatic crystalline alpha2-macroglobulin and its preparation
CO4790097A1 (es) Farmacos
NO942013L (no) Litiumsalt av 2-0-alkylaskorbinsyre

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees